Drug Approval | April 26, 2022
Corbevax gets DCGI nod for Emergency Use in 5-12 years
The approval comes soon after Corbevax was given the nod for 12-15-year group
The approval comes soon after Corbevax was given the nod for 12-15-year group
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
Govt announces vaccination programme for kids and those above 60 years of age
The award recognizes and supports promising women scientists
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
The recommendation has been sent to the DCGI for approval
Corbevax is administered through an intramuscular route with two doses scheduled 28 days apart and is stored between 2 degrees celsius to 8 degrees celsius
Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
It plans to deliver over 300 million doses to the Indian government
Subscribe To Our Newsletter & Stay Updated
